CAL
SPPI

Capital Advisors Ltd’s Spectrum Pharmaceuticals Inc SPPI Stock Holding History

Capital Advisors Ltd’s Portfolio SPPI Stock Details SPPI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-106
Closed – – 1425
2022
Q1 		$0 Buy
+106
New +$98 ﹤0.01% 1294

Other funds holding SPPI

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
ACM
Alethea Capital Management Mercer Island, Washington $195M AUM 51.17% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
E
Ergoteles New York $68.2M AUM 36.16% 1-Year Est. Return

Capital Advisors Ltd's SPPI Position: Q2 2022 in Review

Capital Advisors Ltd sold out of Spectrum Pharmaceuticals Inc (SPPI) in Q2 2022, closing a stake of 106 shares.

Capital Advisors Ltd first reported a position in SPPI in Q1 2022 and held it in 1 quarter. The position peaked at $0 in Q1 2022. 86 funds tracked by Wall St. Rank hold SPPI as of Q2 2022.

  • Capital Advisors Ltd reported no remaining Spectrum Pharmaceuticals Inc position as of Q2 2022 after selling out during the quarter.
  • Capital Advisors Ltd sold 106 Spectrum Pharmaceuticals Inc shares in Q2 2022.
  • Capital Advisors Ltd first reported a position in Spectrum Pharmaceuticals Inc in Q1 2022 and held it in 1 quarter.
  • Capital Advisors Ltd's Spectrum Pharmaceuticals Inc position peaked at $0 in Q1 2022.
  • 86 funds tracked by Wall St. Rank held Spectrum Pharmaceuticals Inc as of Q2 2022.

Based on Capital Advisors Ltd's 13F filing for Q2 2022, filed 5 Aug 2022.